Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

The Clock Is Ticking: Countdown to Metastases.

Siracusa LD, Bussard KM.

PLoS Genet. 2016 Sep 22;12(9):e1006299. doi: 10.1371/journal.pgen.1006299. eCollection 2016 Sep. No abstract available.

2.

An Integrated Genome-Wide Systems Genetics Screen for Breast Cancer Metastasis Susceptibility Genes.

Bai L, Yang HH, Hu Y, Shukla A, Ha NH, Doran A, Faraji F, Goldberger N, Lee MP, Keane T, Hunter KW.

PLoS Genet. 2016 Apr 13;12(4):e1005989. doi: 10.1371/journal.pgen.1005989. eCollection 2016 Apr.

3.

Mitochondrial Genetics Regulate Breast Cancer Tumorigenicity and Metastatic Potential.

Feeley KP, Bray AW, Westbrook DG, Johnson LW, Kesterson RA, Ballinger SW, Welch DR.

Cancer Res. 2015 Oct 15;75(20):4429-36. doi: 10.1158/0008-5472.CAN-15-0074.

4.
5.
6.

An integrated systems genetics screen reveals the transcriptional structure of inherited predisposition to metastatic disease.

Faraji F, Hu Y, Wu G, Goldberger NE, Walker RC, Zhang J, Hunter KW.

Genome Res. 2014 Feb;24(2):227-40. doi: 10.1101/gr.166223.113. Epub 2013 Dec 9.

7.

Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments.

Hu Y, Bai L, Geiger T, Goldberger N, Walker RC, Green JE, Wakefield LM, Hunter KW.

PLoS One. 2013 Aug 28;8(8):e72287. doi: 10.1371/journal.pone.0072287. eCollection 2013.

8.

Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma.

Patel SJ, Molinolo AA, Gutkind S, Crawford NP.

PLoS One. 2013 Apr 19;8(4):e61848. doi: 10.1371/journal.pone.0061848. Print 2013.

9.

Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b.

Goldberger N, Walker RC, Kim CH, Winter S, Hunter KW.

Cancer Res. 2013 Apr 15;73(8):2671-81. doi: 10.1158/0008-5472.CAN-12-3513. Epub 2013 Feb 27.

10.

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.

Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK.

Clin Exp Metastasis. 2013 Jun;30(5):631-42. doi: 10.1007/s10585-013-9567-8. Epub 2013 Feb 1.

11.

The long path from QTL to gene.

Drinkwater NR, Gould MN.

PLoS Genet. 2012 Sep;8(9):e1002975. doi: 10.1371/journal.pgen.1002975. Epub 2012 Sep 20. No abstract available.

12.

Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity.

Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW.

PLoS Genet. 2012 Sep;8(9):e1002926. doi: 10.1371/journal.pgen.1002926. Epub 2012 Sep 20.

13.

Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.

Winter SF, Lukes L, Walker RC, Welch DR, Hunter KW.

PLoS Genet. 2012 May;8(5):e1002735. doi: 10.1371/journal.pgen.1002735. Epub 2012 May 31.

14.

Integrated cross-species transcriptional network analysis of metastatic susceptibility.

Hu Y, Wu G, Rusch M, Lukes L, Buetow KH, Zhang J, Hunter KW.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3184-9. doi: 10.1073/pnas.1117872109. Epub 2012 Jan 30.

15.

Bromodomain-Containing Protein 4: A Dynamic Regulator of Breast Cancer Metastasis through Modulation of the Extracellular Matrix.

Alsarraj J, Hunter KW.

Int J Breast Cancer. 2012;2012:670632. doi: 10.1155/2012/670632. Epub 2011 Oct 26.

16.

Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression.

Hurst DR, Welch DR.

FEBS Lett. 2011 Oct 20;585(20):3185-90. doi: 10.1016/j.febslet.2011.07.045. Epub 2011 Aug 5. Review.

17.

Genome-wide association study of prostate cancer mortality.

Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2869-76. doi: 10.1158/1055-9965.EPI-10-0601. Epub 2010 Oct 26.

18.

A systems biology approach to defining metastatic biomarkers and signaling pathways.

Goldberger NE, Hunter KW.

Wiley Interdiscip Rev Syst Biol Med. 2009 Jul-Aug;1(1):89-96. doi: 10.1002/wsbm.6. Review.

19.

Genetically engineered mouse models in cancer research.

Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.

Adv Cancer Res. 2010;106:113-64. doi: 10.1016/S0065-230X(10)06004-5. Review.

20.

Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.

Masset A, Maillard C, Sounni NE, Jacobs N, Bruyére F, Delvenne P, Tacke M, Reinheckel T, Foidart JM, Coussens LM, Noël A.

Int J Cancer. 2011 Jan 15;128(2):283-93. doi: 10.1002/ijc.25326. Epub 2010 Mar 15.

Supplemental Content

Support Center